economic evaluation direct-acting antiviral therapy chronic hepatitis pubmed ncbi abstract num protease inhibitors boceprevir telaprevir approved united states european union treatment hepatitis infection remarkably effective newly approved therapies accompanied additional side effects considerable costs understanding balance costs effectiveness critical making decisions optimal agents health care systems constrained rising costs goal review facilitate understanding importance cost-effectiveness analyses guiding policy decisions newly approved drugs future therapies hepatitis 
